Why Eli Lilly Execs are Bullish About Its Alzheimer's Drug Solanezumab

When pharma giant Eli Lilly announced in March that it was changing the primary endpoint in a pivotal trial of its Alzheimer’s drug, solanezumab, many on Wall Street might have assumed company’s arduous attempt to reverse the course of the devastating brain disease was dead. Lilly’s shares fell 8%, as everyone from financial analysts to tweeting neurologists speculated the company must have known the drug was doomed to fail in the trial, called Expedition3.

In fact, no one at the company had seen the data from the trial yet, says Eric Siemers, a distinguished medical fellow on the Alzheimer’s disease platform team at Lilly.

Back to news